Breast cancer carrying BRCA mutation may be highly sensitive to DNA-damaging agents. We hypothesized a better outcome for BRCA-mutated (BRCA mut ) metastatic breast cancer (MBC) patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDC AHSCT) versus unaffected BRCA (BRCA wild type; (BRCA wt )) or patients without documented BRCA mutation (BRCA untested (BRCA ut ) . In multivariate analyses, the BRCA mut status was an independent prognostic factor for OS (hazard ratio (HR): 3.08, 95% confidence interval (CI): 1.10-8.64, P = 0.0326) and PFS (HR: 2.52, 95% CI :1.29-4.91, P = 0.0069). In this large series of MBC receiving HDC AHSCT, we report a highly favorable survival outcome in the subset of patients with documented germline BRCA mutations.
INTRODUCTION
Hereditary BRCA genetic mutations are responsible for ∼ 2-3% of breast cancer (BC).
1,2 Functional BRCA1 and BRCA2 proteins are involved in the repair of double-stranded DNA breaks, playing a key role in the error-free homologous recombination pathway. 3, 4 As a result, loss of BRCA1 or BRCA2 function may increase chemosensitivity to cytostatic agents causing DNA damage, such as the creation of DNA interstrand crosslinking, as suggested by preclinical studies. Another DNA-damaging strategy is high-dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation (AHSCT). For this treatment, recent meta-analyses 5, 6 raise the possibility of a modest advantage-in the range of 5 to 10%-in terms of overall survival (OS). Recent studies suggested a role for HDC and HDC-AHSCT in the context of BC, also in view of the fact that this procedure can now be given safely, but failed to clearly identify the subset of patients who may benefit from HDC AHSCT. [7] [8] [9] We hypothesized that HDC AHSCT might be particularly beneficial to patients with BRCA genetic inactivation. Thus, we conducted a retrospective study focusing on metastatic breast cancer (MBC) patients receiving HDC AHSCT with the objective to examine the outcome of patients according to the presence of a documented germline BRCA mutation status.
PATIENTS AND METHODS
We conducted a monocentric retrospective study. The patient population was identified from our institutional cell therapy database, and included all consecutive female patients treated for breast cancer with HDC AHSCT at Institut Paoli-Calmettes between 2003 and 2012. From this cohort, BRCA mut were identified through access to the institutional oncogenetic database. Then, BRCA1/BRCA2 mutational status was classified as either mutated (BRCA mut ) when a constitutional deleterious mutation of either gene was documented or wild-type (BRCA wt ) when no constitutional deleterious mutation of either gene was present despite BRCA testing or untested (BRCA ut ) when no genetic typing had been carried out because of low probability of mutation.
The study was approved by the Institut Paoli-Calmettes institutional review board (Comité d'Orientation Stratégique). All individuals undergoing genetic testing were also required to provide informed consent following counseling and before testing, as per French regulations. No further consent was requested by the institutional review board for the conduct of the present study.
Details about patients' characteristics and their tumors were recorded. HDC AHSCT regimen used in this patient population is presented in Table 1 . Patients received HDC AHSCT either as front-line treatment or as rescue treatment after first progression. AHSCT was performed exclusively with peripheral blood cell grafts, as per institutional procedures. As per institutional procedures, CD34+ cells were mobilized using daily administration of recombinant human G-CSF, blood cells were collected using a SPECTRA or OPTIA cell separator (COBE, Lakewood, CO, USA), transferred to the cell processing facility onsite, cryopreserved and stored in the vapor phase of liquid nitrogen until distribution; before administration, cryopreserved cell products were thawed and washed in the cell processing facility, pooled into a single product that was quickly transferred to the clinical ward and administered to the patient. A minimal number of 2 × 10 6 CD34+ cells, and whenever possible an optimal number of 5 × 10 6 CD34+ cells, were collection targets for each autologous transplantation. Recombinant human G-CSF was administered only to those women who received fewer than 2 × 10 6 CD34+ cells, as measured on the infused pooled, thawed and washed cell product. Trastuzumab treatment was administered before, during and/or after HDC in all HER2+ MBC patients of this cohort. Endocrine therapy was administered when appropriate as maintenance treatment either by tamoxifen or aromatase inhibitors according to the menopausal status.
Descriptive statistics (counts and frequency) were used to describe the categorical variables. The main objective was the analysis of OS according to the BRCA mutation status. Secondary objective was PFS. OS was defined Table 2 . Baseline characteristics of patients according to BRCA mutation Abbreviations: ASCT = autologous stem cell transplantation; BRCA mut = BRCA mutated; BRCA ut = untested BRCA mutation status; BRCA wt = BRCA wild type; HDAC = high-dose chemotherapy; HER2 = overexpression of human epidermal growth factor receptor 2; NEM = endoxan+melphalan+mitoxantrone; PD = progressive disease; SD = stable disease; TN = triple negative. a The χ 2 or Fisher's exact test according to expected scores (see Patients and methods section).
as the time from HDC AHSCT to death as a result of any cause. PFS was defined as the time from HDC AHSCT to progression or death as a result of any cause. Survival curves were generated using Kaplan-Meier method and compared using log-rank test. For detailed characteristics of the patient, after calculating all expected scores, we have tested the difference using Fisher's exact whenever the condition for χ 2 was not reach (expected frequency for each cell 45) and used the χ 2 test in other cases. Adjusted effect of BRCA status on OS and PFS according to other main prognostic variables that differ between different BRCA subgroup (P-valueo 0.10) was examined by multivariate analysis using Cox's proportional hazard regression model. All statistical tests were two sided. The level of statistical significance was set at a P-value of 0.05. Statistical analyses were carried out with the R software version 2.15.2 (Vienna, Austria).
RESULTS
A total of 235 patients was included. Four patients were excluded from OS analysis because of a lack of follow-up. Detailed characteristics of the patients are shown in Table 2 
DISCUSSION
We here report the first study analyzing the outcome of HDC AHSCT according to BRCA status in MBC.
Although results of preclinical and clinical studies indicate that loss of BRCA function confers sensitivity to commonly used DNA-damaging chemotherapy in BC, [10] [11] [12] there is as yet no consensus regarding the most effective chemotherapy regimen in BRCA mutation carriers. Despite the small size of the population of interest, our results suggest an impressively favorable outcome in BRCA mut patients receiving HDC AHSCT when these patients are compared with BC population of women who had not been tested for BRCA mutations or tested negative for which this treatment had been carried out. Few studies have assessed the sensitivity to standard first-line chemotherapy and outcome of metastatic BRCA1/2-associated breast cancer compared with sporadic breast cancer patients: Kriege et al. 13 concluded that BRCA2-associated breast cancer is more sensitive to standard first-line chemotherapy for metastatic breast cancer in comparison with sporadic breast cancer, whereas no statistically significant higher sensitivity was observed for BRCA1-associated breast cancer. Conversely, Bayraktar et al.
14 suggested that BRCA1 carriers diagnosed with MBC had worse outcomes when compared with BRCA2 carriers or noncarriers. However, the differences in outcome did not reach statistical significance. Other reports have suggested differential outcome according to BRCA status. Another Dutch study examined activity of taxane-based regimens in BRCA or sporadic MBC patients and found lower response rate and PFS in BRCA1 patients. 15 Alternatively, and consistent with our results, a high response rate and a favorable outcome was observed in BRCA1/2-mutated MBC patients exposed to DNA-damaging strategy, such as platinum derivatives 16 or trabectidine. 17 Taken together, these data identify BRCA1/2-associated cancers as particularly sensitive to DNA-damaging approaches, suggesting that the gain in OS for BRCA mut individuals observed in our small group of patients may specifically be a consequence of the administration of HDC.
It is noticeable that meta-analyses of large prospective studies conducted in adjuvant or metastatic patients support an OS benefit from HDC in younger patients 6, 18, 19 and/or those harboring triplenegative tumors. 5 This is possibly because of the highest rate of BRCA mut patients in these subgroups, although these data were not available or not collected in these studies conducted in MBC [20] [21] [22] [23] [24] [25] or high-risk BC. 9, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In our study, BRCA mut patients with MBC had a better prognosis in multivariate analyses, regardless of triplenegative status and age. Recent results indicate that tumor DNA repair deficiency might be found beyond those germline mutations, the so-called BRCAness, 39, 40 that could also predict for HDC benefit. For instance, a comparative genomic hybridization-based classifier, developed from BRCA1-mutated BC in order to identify tumors with loss of BRCA1 regardless of their genetic status, was able to identify stage III BC patients deriving huge benefit from adjuvant HDC compared with conventional treatment. 41, 42 Our study has several limitations. The sample size is small, as we only identified 15 mutation carriers. The number of BRCA carriers is too small to allow for any separate analysis of BRCA1 and BRCA2 mutations carriers. It is possible that few untested patients in the control group harbored BRCA mutations; consistent with recommendations for genetic testing, molecular screening for BRCA mutations was proposed only to patients who were considered at fairly high risk of germline mutation, mostly based on family history. However, there was no significant difference in OS between BRCA ut and BRCA wt groups. In addition, the frequency of BRCA mutations in our cohort of patients (6.3%) is comparable to published data. 1 Despite its retrospective nature, this study suggests an unexpected positive outcome in a small subset of patients with documented BRCA mutations. In this cohort, at the time of therapeutic decision, BRCA status was not used or even known.
CONCLUSION
In this series of MBC receiving HDC AHSCT, BRCA mut individuals had a better outcome than their BRCA wt/ut counterparts. These results add another piece to existing data that suggest an exquisite sensitivity to DNA-damaging treatment, including HDC AHSCT, of BC associated with BRCA1/2 mutations. Thus, HDC and AHSCT may represent a useful alternative for appropriately identified tumor subsets, representing an unexpected example of molecularly targeted chemotherapy. 
